Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma
暂无分享,去创建一个
M. Dimopoulos | S. Giannouli | K. Konstantopoulos | E. Kastritis | M. Gavriatopoulou | E. Terpos | M. Roussou | D. Ziogas | M. Migkou | D. Fotiou | E. Eleutherakis-Papaiakovou | I. Panagiotidis | A. Zomas | Eftychia Kafantari
[1] H. Goldschmidt,et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Dimopoulos,et al. Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy , 2014 .
[3] P. Sonneveld,et al. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders , 2012, Haematologica.
[4] M. Dimopoulos,et al. Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma. , 2011, Clinical lymphoma, myeloma & leukemia.
[5] H. Avet-Loiseau,et al. The impact of genomics on the management of myeloma. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.
[6] J. Shaughnessy,et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. , 2011, Blood.
[7] M. Dimopoulos,et al. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents , 2010, European journal of haematology.
[8] H. Avet-Loiseau. Role of genetics in prognostication in myeloma. , 2007, Best practice & research. Clinical haematology.
[9] G. Morgan,et al. Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma , 2005, Leukemia.
[10] J. Crowley,et al. International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Bart Barlogie,et al. Genetics and Cytogenetics of Multiple Myeloma , 2004, Cancer Research.
[12] Terry L. Smith,et al. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. , 1991, Annals of internal medicine.
[13] S. Salmon,et al. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.